Specific Binding, Uptake, and Transport of ICAM-1-Targeted Nanocarriers Across Endothelial and Subendothelial Cell Components of the Blood–Brain Barrier

ABSTRACTPurposeThe blood–brain barrier (BBB) represents a target for therapeutic intervention and an obstacle for brain drug delivery. Targeting endocytic receptors on brain endothelial cells (ECs) helps transport drugs and carriers into and across this barrier. While most receptors tested are associated with clathrin-mediated pathways, clathrin-independent routes are rather unexplored. We have examined the potential for one of these pathways, cell adhesion molecule (CAM)-mediated endocytosis induced by targeting intercellular adhesion molecule -1 (ICAM-1), to transport drug carriers into and across BBB models.MethodsModel polymer nanocarriers (NCs) coated with control IgG or antibodies against ICAM-1 (IgG NCs vs. anti-ICAM NCs; ~250-nm) were incubated with human brain ECs, astrocytes (ACs), or pericytes (PCs) grown as monocultures or bilayered (endothelial+subendothelial) co-cultures.ResultsICAM-1 was present and overexpressed in disease-like conditions on ECs and, at a lesser extent, on ACs and PCs which are BBB subendothelial components. Specific targeting and CAM-mediated uptake of anti-ICAM NCs occurred in these cells, although this was greater for ECs. Anti-ICAM NCs were transported across endothelial monolayers and endothelial+subendothelial co-cultures modeling the BBB.ConclusionsCAM-mediated transport induced by ICAM-1 targeting operates in endothelial and subendothelial cellular components of the BBB, which may provide an avenue to overcome this barrier.

[1]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.

[2]  A. Malik,et al.  Mechanisms regulating endothelial cell barrier function. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[3]  Vladimir P Torchilin,et al.  Multifunctional nanocarriers. , 2006, Advanced drug delivery reviews.

[4]  T. Bhowmick,et al.  Transport of nanocarriers across gastrointestinal epithelial cells by a new transcellular route induced by targeting ICAM-1. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Samir Mitragotri,et al.  Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  David H Rowitch,et al.  Astrocytes and disease: a neurodevelopmental perspective. , 2012, Genes & development.

[7]  W. Pardridge,et al.  Biopharmaceutical drug targeting to the brain , 2010, Journal of drug targeting.

[8]  M. Wood,et al.  Exosome nanotechnology: An emerging paradigm shift in drug delivery , 2011, BioEssays : news and reviews in molecular, cellular and developmental biology.

[9]  Silvia Muro,et al.  Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[10]  R. Duncan The dawning era of polymer therapeutics , 2003, Nature Reviews Drug Discovery.

[11]  J. Nutt,et al.  Strategies to advance translational research into brain barriers , 2008, The Lancet Neurology.

[12]  D. Toomre,et al.  Lymphocyte transcellular migration occurs through recruitment of endothelial ICAM-1 to caveola- and F-actin-rich domains , 2006, Nature Cell Biology.

[13]  A. Malik,et al.  Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function , 2002, Histochemistry and Cell Biology.

[14]  T. Bhowmick,et al.  Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor , 2013, Journal of Inherited Metabolic Disease.

[15]  Michael Loran Dustin,et al.  A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. , 1986, Journal of immunology.

[16]  T. Bhowmick,et al.  Intercellular Adhesion Molecule 1 Engagement Modulates Sphingomyelinase and Ceramide, Supporting Uptake of Drug Carriers by the Vascular Endothelium , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[17]  T. Yue,et al.  Upregulation of intercellular adhesion molecule 1 (ICAM-1) on brain microvascular endothelial cells in rat ischemic cortex. , 1994, Brain research. Molecular brain research.

[18]  F. D’Acquisto,et al.  Pericytes support neutrophil subendothelial cell crawling and breaching of venular walls in vivo , 2012, The Journal of experimental medicine.

[19]  L. Khawli,et al.  Drug delivery across the blood-brain barrier. , 2013, Molecular pharmaceutics.

[20]  Silvia Muro,et al.  Challenges in design and characterization of ligand-targeted drug delivery systems. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[21]  S. Muro,et al.  In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors. , 2013, Biomaterials.

[22]  William A Banks,et al.  Blood-brain barrier as a regulatory interface. , 2010, Forum of nutrition.

[23]  C. Betsholtz,et al.  Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. , 2011, Developmental cell.

[24]  R. Langer,et al.  Drug delivery and targeting. , 1998, Nature.

[25]  V. Muzykantov,et al.  A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1 , 2003, Journal of Cell Science.

[26]  R. Stan Endocytosis pathways in endothelium: how many? , 2006, American journal of physiology. Lung cellular and molecular physiology.

[27]  W. Frey,et al.  Intranasal delivery to the central nervous system: mechanisms and experimental considerations. , 2010, Journal of pharmaceutical sciences.

[28]  Ignacio A. Romero,et al.  Development of a three-dimensional, all-human in vitro model of the blood–brain barrier using mono-, co-, and tri-cultivation Transwell models , 2011, Journal of Neuroscience Methods.

[29]  Silvia Muro,et al.  Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[30]  D D Breimer,et al.  The blood-brain barrier in neuroinflammatory diseases. , 1997, Pharmacological reviews.

[31]  J. Mandell,et al.  Phagocytic clearance in neurodegeneration. , 2011, The American journal of pathology.

[32]  V. Muzykantov,et al.  Endothelial endocytic pathways: gates for vascular drug delivery. , 2004, Current vascular pharmacology.

[33]  J. Schnitzer,et al.  Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo. , 2001, Advanced drug delivery reviews.

[34]  S. Shioda,et al.  Delayed expressed TNFR1 co-localize with ICAM-1 in astrocyte in mice brain after transient focal ischemia , 2004, Neuroscience Letters.

[35]  K. Ley,et al.  Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation , 2004, Nature Reviews Immunology.

[36]  Silvia Muro,et al.  Endothelial Targeting of High-Affinity Multivalent Polymer Nanocarriers Directed to Intercellular Adhesion Molecule 1 , 2006, Journal of Pharmacology and Experimental Therapeutics.

[37]  W. Pardridge,et al.  Blood-brain barrier delivery. , 2007, Drug discovery today.

[38]  E. Benveniste,et al.  ICAM-1-Induced Expression of Proinflammatory Cytokines in Astrocytes: Involvement of Extracellular Signal-Regulated Kinase and p38 Mitogen-Activated Protein Kinase Pathways1 , 2000, The Journal of Immunology.

[39]  M. Gómez-Lechón,et al.  Endocytosis and transcytosis in growing astrocytes in primary culture. Possible implications in neural development. , 2000, The International journal of developmental biology.

[40]  Silvia Muro,et al.  Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders , 2012, Drug Delivery and Translational Research.